Member Info for Krone

Https://pharmaphorum.com/news/biogen-pens-1bn-deal-buy-immunology-biotech-raythera

Hi HBD,

Thanks yes, I appreciate that we’re targeting Jak1….it was more the deal size that caught my eye.

All the best.

Https://www.fiercebiotech.com/biotech/lilly-23b-ajax-deal-first-clinical-data-jak-inhibitor-works-right-out-gate?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=8331F3744801G2C

It will be interesting to see if anything SRA737 related emerges from the ASCO conference…..

Perhaps the Chairman’s update will kick start some momentum so the SP gets closer to the temperature…..

Https://www.fiercebiotech.com/biotech/lilly-continues-ma-streak-23b-deal-next-gen-jak-inhibitor-biotech-ajax

In this real-world study, deucravacitinib showed significant and sustained effectiveness, together with a favorable safety profile, in patients with moderate-to-severe plaque psoriasis. These findings support its role as an effective oral targeted therapy in routine clinical practice.

https://academic.oup.com/ced/advance-article-abstract/doi/10.1093/ced/llag187/8662642?redirectedFrom=fulltext&utm_source=chatgpt.com

Thanks Potnak, sleuthing at its best!

Particularly enticing “ The primary researcher behind the breakthrough showing SRA737’s immune-remodeling capability.”

ATB

Https://www.businessweekly.co.uk/posts/sareum-continues-fightback-in-six-months-to-end-december?lh_aid=28468&lh_cid=czv7w8u4x2&lh_em=info%40amundsen.co.uk&di=09b37b9f3c0e7da08155cc085206e6ce

Good morning C79,

Excellent finds as always!

The dot joining will surely end up with a masterpiece…or is that painting by numbers…you get the gist!

Thanks so much.

ATVB

Notice of Allowance received from US Patent and Trademark Office for an application protecting the crystal form of SRA737 drug substance, extending patent protection until at least April 2041.

Given that SRA737 is likely to be the most significant near term catalyst to get the SP moving, it would be encouraging to get some hint of how/if negotiations are proceeding, albeit with the constraints of the RNS rules.

Do any other long term investors start to get the feelings of quiet anticipation on a Sunday evening which by Monday morning have turned into mildly adrenaline fuelled naive expectations that this week may just be different, from the many hundreds of previous weeks, and there may be some substantive news…..only to get to Friday once again with nothing and the accompanying sinking stomach feeling. God knows we all deserve a medal for patience!

Https://qtx.omeclk.com/portal/wts/ue%5EcmQ6kmV2bc-n%5BaR%5E%5E66srkEnv2jrcOP7v-sPdOa

Clearly Dr Parker is listening to investors!

https://x.com/sparksinsurrey/status/2014280979293036549?s=46&t=_cUs6qcowyQbbF4MoPYSCw

Good morning C79 and many thanks as always for your post.

The weight of evidence supporting the progression of SRA737 is substantial and it would astonishing if we don’t hear something positive soon!

ATVB

As announced on 10 October 2025, the Company discontinued its 16-week GLP preclinical toxicology study for SDC-1801 following unexpected safety findings, observed by the third-party provider of the study. These findings occurred at a higher incidence in control-group animals that received an inactive dosing solution compared to those dosed with SDC-1801.

The Company has now appointed a different leading global CRO, with extensive experience in long-term toxicology studies, to restart the Phase 2-enabling toxicology programme. Prior to commencing the full 16-week toxicology study, the Company will conduct a separate pharmacokinetic (PK) study to evaluate four different formulations, three liquid formulations for gavage dosing and one capsule formulation. This five-day study will provide valuable data on both tolerability and exposure levels, helping to optimise the formulation selection for the full toxicology study. The carrier formulation is specific to the animal toxicology studies only and will not form part of any human dosing regimen.

The PK study is expected to commence imminently, with the full toxicology study expected to restart as early as possible in Q1 2026. Both studies will be completed using the Company's existing cash resources and the existing toxicology batch of SDC-1801.

Hi ajithoth,

Thank you, that’s very helpful.

ATB

Not sure of the significance, if any, of this patent update?

https://register.epo.org/application?number=EP19794095&tab=main

Good morning C79 and many thanks as always for some excellent digging with extremely exciting conclusions. Of course the suitors of SRA737 will be well aware of the massive potential! Taking all available information into account and the palpable optimism from JR on Tuesday combined with the much greater granularity of detail, it must be full steam ahead for a deal early in the new year, at which point the naysayers will have large helpings of humble pie to digest.

All the best.